Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk's bid to challenge Sanofi's dominance of the long-lasting insulin market hit another snag after U.S. regulators delayed approval of the Danish drugmaker's degludec until after an expert review.
Novo has said degludec could become a blockbuster - defined by the industry as a treatment that generates more than $1 billion in sales within five years of its launch. But some analysts see the drug with peak sales potential as high as the current $5 billion for Sanofi's top-selling Lantus.
http://uk.reuters.com/article/2012/07/18/us-novonordisk-degludec-fda-idUKBRE86H09120120718
Novo has said degludec could become a blockbuster - defined by the industry as a treatment that generates more than $1 billion in sales within five years of its launch. But some analysts see the drug with peak sales potential as high as the current $5 billion for Sanofi's top-selling Lantus.
http://uk.reuters.com/article/2012/07/18/us-novonordisk-degludec-fda-idUKBRE86H09120120718